Survodutide
Dual GLP-1/glucagon agonist, code BI 456906
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
No package insert, no approved dose
This compound has no FDA registration — checked in the label database on September 4, 2026. That does not make it safer than semaglutide or tirzepatide, which carry a black box warning: it makes it less known. There is no approved titration ladder, no defined maximum dose and no official contraindication list to compare with the tables on this page.
The related analogs that already have a package insert carry a thyroid C-cell tumor warning — and tirzepatide is contraindicated in medullary thyroid carcinoma and MEN 2 in the package inserts of both countries, while semaglutide is only in the United States. The full audit is in The GLP-1s against the package insert.
Summary
29-amino-acid peptide developed by Boehringer Ingelheim with Zealand Pharma. Research code BI 456906. Weekly and subcutaneous, it acts on two targets: GLP-1 and glucagon receptors. Still under investigation, with relevant data in steatohepatitis.
Quick reference
- Mechanism
- Dual GLP-1 + glucagon agonist — unlike tirzepatide, which hits GLP-1 + GIP.
- Route
- Subcutaneous injection, 1×/week.
- Top dose in the trial
- 4.8 mg 1×/week in phase 2 in obesity, after 20 weeks of escalation.
- Phase 3 result
- 16.6% weight loss at 76 weeks, versus 3.2% on placebo (SYNCHRONIZE-1).
Trial-studied dose escalation (Phase 2)
| Arm | Mean Weight Loss | Note |
|---|---|---|
| Placebo | -2,8% | Reference arm. |
| 0.6 mg 1×/week | -6,2% | Lowest studied dose. |
| 2.4 mg 1×/week | -12,5% | Mid dose. |
| 3.6 mg 1×/week | -13,2% | Mid-high dose. |
| 4.8 mg 1×/week | -14.9% in the main analysis | Top dose; people who completed the trial reached around 18.7%. This is not a dosing recommendation. |
Survodutide Reconstitution Guide
| Vial size | BAC water added | Concentration | 1 unit (U-100) equals |
|---|---|---|---|
| 6 mg | 1.0 mL | 6.0 mg/mL | 0.060 mg (60 mcg) |
| 6 mg | 2.0 mL | 3.0 mg/mL | 0.030 mg (30 mcg) |
| 10 mg | 1.0 mL | 10.0 mg/mL | 0.100 mg (100 mcg) |
| 10 mg | 2.0 mL | 5.0 mg/mL | 0.050 mg (50 mcg) |
Survodutide vs Retatrutide vs Tirzepatide vs Semaglutide
| Peptide | Receptor targets | Top reported weight loss | Route | FDA status |
|---|---|---|---|---|
| Survodutide (BI 456906) | GLP-1 + Glucagon | 16.6% (Phase 3 SYNCHRONIZE-1, 76 weeks) | Subcutaneous, 1×/week | Investigational |
| Retatrutide | GLP-1 + GIP + Glucagon (triple) | 24.2% (Phase 2, 48 weeks) | Subcutaneous, 1×/week | Investigational |
| Tirzepatide (Mounjaro / Zepbound) | GLP-1 + GIP | 20.9% (SURMOUNT-1, 72 weeks) | Subcutaneous, 1×/week | FDA-approved (T2D and obesity) |
| Semaglutide (Ozempic / Wegovy / Rybelsus) | GLP-1 only | 14.9% (STEP 1, 68 weeks) | Subcutaneous, 1×/week (oral Rybelsus daily) | FDA-approved (T2D and obesity) |
| CagriSema (cagrilintide + semaglutide) | GLP-1 + Amylin | 22.7% (REDEFINE-1 Phase 3) | Subcutaneous, 1×/week | Investigational |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.